OCEAN Study for EGPA
Trial Objectives
.jpg?lang=en-US)
People with eosinophilic granulomatosis with polyangiitis (EGPA) are needed for the OCEAN clinical trial. The study compares two medications: mepolizumab (NUCALA), which is administered by an injection once a month, and depemokimab, an investigational medication that is injected twice a year. Researchers want to understand if depemokimab is as safe and effective as mepolizumab. Volunteers will receive a blood draw and will be randomly assigned to receive an injection of one of the two medications.
Who Can Participate
Adults with EGPA that has worsened or returned after previous treatment and are taking a corticosteroid or immunosuppressant
Age: 18+ Gender: Any
Estimated Time Commitment
Once a month visits for approximately 15 months
Payment & Reimbursement
Payment: Provided
Travel Reimbursement: Available
.jpg?lang=en-US)
Trial Location
National Jewish Main Campus, Denver, CO
Trial Sponsors
GSK
Principal Investigators
Michael E. Wechsler, MD, MMSc
Co-Investigators
Vamsi P. Guntur, MD, MSc